Bedrijfsoverzicht
Pulmonx Corporation is a commercial-stage medical technology company dedicated to delivering minimally invasive treatments specifically designed for patients suffering from severe emphysema, a critical manifestation of chronic obstructive pulmonary disease. The entity operates within the healthcare sector, focusing on the medical devices industry, which implies a specialized environment requiring rigorous regulatory compliance and technological innovation. The company's current scale is characterized by a market capitalization of $57.86M, an annual revenue of $90.50M, and an employee base of 296 individuals. These valuation and revenue figures indicate that Pulmonx occupies a niche position in the market, reflecting a small-cap status where growth potential is often weighed against significant operational costs and the need for substantial capital investment to advance its product portfolio, such as the Zephyr Endobronchial Valve and the Chartis Pulmonary Assessment System.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $90.50M, yet it posted a net income of -$54,003,000 and an EBITDA of -$52,609,000, revealing a substantial gap between top-line generation and profitability. This disparity highlights a cost structure where operating expenses significantly outweigh gross profits, a common characteristic in early-to-mid stage medical device development but one that currently constrains net earnings. Free cash flow stands at -$12,531,250, indicating that the company is burning cash to fund its operations and product development, which limits immediate financial flexibility for large-scale acquisitions or aggressive shareholder returns without additional capital raises. Margin analysis shows a Gross Margin of 74.2%, suggesting efficient production costs relative to sales, contrasted sharply by an Operating Margin of -43.8% and a Profit Margin of -59.7%, which reflect high overhead costs and losses before interest and taxes. The balance sheet presents a complex picture with cash reserves of $69.75M against total debt of $56.36M, resulting in a Debt to Equity ratio of 104.15%, which suggests a leveraged position despite the presence of significant liquid assets. Liquidity is robust, evidenced by a Current Ratio of 5.07, indicating that the company holds ample short-term assets to cover its short-term liabilities without immediate risk of insolvency. Return on Equity stands at -77.2% and Return on Assets at -23.0%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a typical phase for companies investing heavily in R&D prior to commercial scale-up.
Waarderingsbeoordeling
Valuation metrics for Pulmonx show a Trailing P/E Ratio (TTM) of N/A due to negative earnings, while the Forward P/E is listed at -1.36, implying that future earnings estimates are also negative or that the market is pricing the stock based on non-earnings multiples. The Price to Book ratio is 1.05, indicating that the market values the company at roughly one dollar above its net asset value, suggesting a neutral stance rather than a significant premium or discount over book value. Alternative valuation measures include a Price to Sales ratio of 0.64 and an EV/EBITDA of -0.84, which suggest the market is pricing the stock based on revenue generation rather than profitability, a standard approach for loss-making biotech and medtech firms. The stock's price volatility is contextualized by its 52-Week High of $5.49 and 52-Week Low of $1.13, providing a range within which the share price has fluctuated over the last year. The Beta value of 0.19 indicates that the stock exhibits significantly lower price volatility relative to the broader market, moving much less than the general market index. These metrics collectively paint a picture of a speculative asset where valuation is driven by pipeline potential rather than current cash flow generation.
Growth & Income
Revenue growth year-over-year is recorded at -4.9%, while earnings growth is N/A due to the absence of positive earnings in the prior periods. The decline in revenue suggests a contraction in sales volume or pricing pressure, and since earnings are negative, the concept of earnings growing faster or slower than revenue is currently abstract, though the loss margin has widened relative to the shrinking revenue base. As a non-dividend payer, the company does not distribute a dividend yield, which is listed as N/A, nor does it have a payout ratio, as the Payout Ratio stands at 0.0%. This structure implies that the company retains all available capital, albeit in the form of cash reserves rather than distributed income, to reinvest into research, development, and commercialization efforts to achieve future profitability. Consequently, the overall growth and income profile is defined by revenue contraction and a complete absence of current income generation, relying entirely on the expectation of future product approvals or market expansion to restore positive cash flows.